United States - English - NLM (National Library of Medicine)

jazz pharmaceuticals, inc. - asparaginase erwinia chrysanthemi (unii: d733et3f9o) (asparaginase - unii:g4fq3cky5r) - asparaginase 10000 [iu] in 1 ml - erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (all) who have developed hypersensitivity to e. coli -derived asparaginase. erwinaze is contraindicated in patients with a history of: risk summary based on findings from animal reproduction studies, erwinaze can cause fetal harm when administered to a pregnant woman. in animal reproduction studies, intramuscular administration of asparaginase erwinia chrysanthemi to pregnant rats and rabbits during organogenesis at doses approximately 0.005-0.5 times the maximum recommended human dose resulted in structural abnormalities and embryo-fetal mortality (see data). there are no available data on erwinaze use in pregnant women to evaluate the drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. advise pregnant women of the potential risk to the fetus. the estimated background risk of major birth defects and miscarriage for the ind

United States - English - NLM (National Library of Medicine)

changzhou qianhong bio-pharma co., ltd - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) -

Malta - English - Medicines Authority

medac gesellschaft fur klinische spezialpräparate mbh theaterstr. 6 22880 wedel, germany - l, asparaginase - powder for solution for injection - l-asparaginase 10000 iu - antineoplastic agents

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) -

United States - English - NLM (National Library of Medicine)

cbschem limited - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) -

United States - English - NLM (National Library of Medicine)

jazz pharmaceuticals, inc. - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) - rylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (all) and lymphoblastic lymphoma (lbl) in adult and pediatric patients 1 month or older who have developed hypersensitivity to e. coli -derived asparaginase. rylaze is contraindicated in patients with a history of: risk summary based on findings from animal reproduction studies, rylaze can cause fetal harm when administered to a pregnant woman. there are no available data on rylaze use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproductive and developmental toxicity studies, intramuscular administration of asparaginase erwinia chrysanthemi to pregnant rats and rabbits during organogenesis resulted in structural abnormalities and embryo-fetal mortality (see data ) at exposures below those in patients at the recommended human dose. advise pregnant women of the potential risk to a fet

United States - English - NLM (National Library of Medicine)

loka biosciences pvt. ltd - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) -

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) -

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) -

United States - English - NLM (National Library of Medicine)

sajjala bio labs private limited - asparaginase (unii: g4fq3cky5r) (asparaginase - unii:g4fq3cky5r) -